Olmesartan Medoxomilo + Hidroclorotiazida Azevedos (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Azevedos, is an angiotensin II receptor blocker presented as a oral tablet for hypertension management in adults. It combines olmesartan medoxil with hydrochlorothiazide to enhance blood pressure control.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/hydrochlorothiazide is indicated for cardiovascular conditions that involve elevated blood pressure. - Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive heart disease: assists in decreasing cardiac workload and preventing disease progression. - Chronic kidney disease with hypertension: aids in slowing renal function decline associated with high blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Acute kidney injury - Significant drop in blood pressure (hypotension) - Elevated liver enzymes - Angio‑edema involving the face or throat

When prescribing olmesartan medoxil/hydrochlorothiazide, clinicians should consider several safety aspects. - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially in patients on other diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start with lower doses and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy and affect renal function. - ACE inhibitors or other ARBs: additive hypotensive effect, monitor blood pressure. - Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.